Gilead, leo pharma

Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal wit | Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now,
Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.
Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO
Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases
Gilead Sciences and LEO Pharma said they formed a strategic partnership to focus on the potential treatment of patients with inflammatory diseases.
PharmaTimes5h
Gilead and LEO Pharma partner to develop oral STAT6 program
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
ENDPOINTS NEWS2h
Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...
devdiscourse9h
Major Pharmaceutical Mergers and Developments Shake Up the Industry
Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...
pharmaphorum5d
LEO closes on first approval for chronic hand eczema drug
Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.